Teut Michael, Hirschberg Ute, Elies Michael K, Lüdtke Rainer, Albrecht Henning, Dahler Jörn, Schnegg Christoph, Witt Claudia M
Institut für Sozialmedizin, Epidemiologie und Gesundheitsökonomie, Charité Universitätsmedizin Berlin, Deutschland.
Forsch Komplementmed. 2011;18(2):91-6. doi: 10.1159/000325372. Epub 2011 Apr 15.
For more than 200 years, homeopathic doctors have been carrying out homeopathic drug provings (HDPs),which embodies the traditional self drug testing, an integral part of the homeopathic medical profession. However,according to national authorities, testing homeopathic drugs is a phase I clinical trial for which the German Federal Drug Law applies. Adapting a 200-year-old primary qualitative study design to modern drug law and Good Clinical Practice Guidelines generates several difficulties, in particular, blinding, informed consent and the classification of adverse events. In addition, in Germany naturopaths (German: ‘Heilpraktiker’) are excluded from leading HDP trials. The costs are climbing, and the organizational over heads for a HDP are enormous. Implications for the future are discussed.
200多年来,顺势疗法医生一直在进行顺势疗法药物验证(HDPs),这体现了传统的自我药物测试,是顺势疗法医学专业不可或缺的一部分。然而,根据国家当局的说法,测试顺势疗法药物属于适用德国联邦药品法的I期临床试验。将具有200年历史的初级定性研究设计调整为符合现代药品法和《药物临床试验质量管理规范》会产生一些困难,特别是盲法、知情同意和不良事件的分类。此外,在德国,自然疗法医生(德语:“Heilpraktiker”)被排除在主导HDP试验之外。成本在不断攀升,HDP的组织管理费用极高。本文讨论了对未来的影响。